If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-27. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Each facility operating an x-ray unit shall have sufficient personnel with appropriate expertise. The person responsible for radiation protection or one or more Radiation Safety Officers shall have appropriate qualifications, which shall be regularly updated. X-ray examinations may be technically performed by any other staff member of a medical or dental practice if they are under the direct supervision and responsibility of the person responsible and if they have knowledge of radiation protection. This knowledge of radiation protection has been required since the amendment of the X-ray Ordinance in 1987; medical and dental assistants (then called medical assistants or dental assistants) received this additional training in 1990. The regulations for the specialty of radiology were tightened by the Radiation Protection Act, which came into force on October 1, 2017. The handling of radioactive substances and ionizing radiation (if not covered by the X-ray Ordinance) is regulated by the Radiation Protection Ordinance (StrlSchV). Section 30 StrlSchV § 30 StrlSchV (in German) defines the "Required expertise and knowledge in radiation protection".
=== Redox-responsive nanogels === Redox-responsive nanogels generally contain crosslinks formed by disulfide bonds or specific crosslinking agents. Nanogels made of bioreducible and bifunctional monomers can also be used. In the presence of reducing agents such as glutathione, thioredoxin and peroxiredoxin, these nanogels respond by releasing their cargo. Given that these reducing agents and several others are found in larger concentrations inside cells compared to their external environment, redox-responsive nanogels are a promising strategy for targeted intracellular delivery.
Firefox Missile Command Raid over Moscow SDI Metal Gear Solid 3: Snake Eater Metal Gear Solid V: The Phantom Pain DEFCON World in Conflict Crisis in the Kremlin Call of Duty: Black Ops Call of Duty: Black Ops: Declassified Call of Duty: Black Ops II Call of Duty: Black Ops Cold War Fallout (series) Command and Conquer: Red Alert Tetris
Sources: en.wikipedia.org
1991: Invercargill re-proclaimed a city. 1992: Nelson-Marlborough Regional Council abolished by a Local Government Amendment Act. Of its territorial authorities, the Kaikōura District was transferred to the Canterbury Region, and Nelson City and Tasman and Marlborough districts became unitary authorities. 1995: The Chatham Islands County was dissolved and reconstituted by an Act of Parliament as the "Chatham Islands Territory", with powers similar to those of territorial authorities and some functions similar to those of a regional council. 2004: Tauranga became a city again on 1 March. 2006: The Banks Peninsula District merged into Christchurch as a result of a 2005 referendum. 2010: Auckland Council, a unitary authority, replaced seven local councils and the regional council. Reports on completed reorganisation proposals since 1999 are available on the Local Government Commission's site (link below).
== Arrest, trial, and conviction == In July 2020, Mays was arrested and charged with the murders of eight individuals. The charges were later reduced to seven second-degree murders and one count of intent to commit murder involving the death of the 92-year-old United States Navy veteran Russell R. Posey Sr., who died two weeks after he had been injected with insulin. Prosecutors stated that there were approximately twenty suspicious deaths while Mays worked at the hospital, but charges were brought only for the cases that were believed to have sufficient evidence. On July 14, 2020, Mays pleaded guilty in the United States District Court for the Northern District of West Virginia in Clarksburg to seven counts of second-degree murder and one count of attempted murder. By pleading guilty to all of the charges, Mays waived the right to have the case presented to a grand jury. Mays wept openly in court and admitted that she had murdered the patients. Mays offered no motive but claimed to be taking medication for post-traumatic stress disorder (PTSD). She was held in custody at the West Virginia Regional Jail and Correctional Facility until her sentencing. An interview with Mays after her guilty plea was included in a report, released after the sentencing by the Department of Veterans Affairs' Office of Inspector General, that detailed deficiencies at the hospital.
In the molecule lawrencium dihydride (LrH2), which is predicted to be bent, the 6d orbital of lawrencium is not expected to play a role in the bonding, unlike that of lanthanum dihydride (LaH2). LaH2 has La–H bond distances of 2.158 Å, while LrH2 should have shorter Lr–H bond distances of 2.042 Å due to the relativistic contraction and stabilization of the 7s and 7p orbitals involved in the bonding, in contrast to the core-like 5f subshell and the mostly uninvolved 6d subshell. In general, molecular LrH2 and LrH are expected to resemble the corresponding thallium species (thallium having a 6s26p1 valence configuration in the gas phase, like lawrencium's 7s27p1) more than the corresponding lanthanide species. The electron configurations of Lr+ and Lr2+ are expected to be 7s2 and 7s1 respectively. However, in species where all three valence electrons of lawrencium are ionized to give at least formally the Lr3+ cation, lawrencium is expected to behave like a typical actinide and the heavier congener of lutetium, especially because the first three ionization potentials of lawrencium are predicted to be similar to those of lutetium. Hence, unlike thallium but like lutetium, lawrencium would prefer to form LrH3 than LrH, and LrCO is expected to be similar to the also unknown LuCO, both metals having valence configuration σ2π1 in their monocarbonyls. The pπ–dπ bond is expected to be seen in LrCl3 just as it is for LuCl3 and more generally all the LnCl3.
Sources: en.wikipedia.org
1 μg RAE = 1 μg retinol from food or supplements 1 μg RAE = 2 μg all-trans-β-carotene from supplements 1 μg RAE = 12 μg of all-trans-β-carotene from food 1 μg RAE = 24 μg α-carotene or β-cryptoxanthin from food RAE takes into account carotenoids' variable absorption and conversion to vitamin A by humans better than and replaces the older retinol equivalent (RE) (1 μg RE = 1 μg retinol, 6 μg β-carotene, or 12 μg α-carotene or β-cryptoxanthin). RE was developed 1967 by the United Nations/World Health Organization Food and Agriculture Organization (FAO/WHO).
Stimulates the uptake of glucose – Insulin decreases blood glucose concentration by inducing intake of glucose by the cells. This is possible because Insulin causes the insertion of the GLUT4 transporter in the cell membranes of muscle and fat tissues which allows glucose to enter the cell. Increased fat synthesis – insulin forces fat cells to take in blood glucose, which is converted into triglycerides; decrease of insulin causes the reverse. Increased esterification of fatty acids – forces adipose tissue to make neutral fats (i.e., triglycerides) from fatty acids; decrease of insulin causes the reverse. Decreased lipolysis in – forces reduction in conversion of fat cell lipid stores into blood fatty acids and glycerol; decrease of insulin causes the reverse. Induced glycogen synthesis – When glucose levels are high, insulin induces the formation of glycogen by the activation of the hexokinase enzyme, which adds a phosphate group in glucose, thus resulting in a molecule that cannot exit the cell. At the same time, insulin inhibits the enzyme glucose-6-phosphatase, which removes the phosphate group. These two enzymes are key for the formation of glycogen. Also, insulin activates the enzymes phosphofructokinase and glycogen synthase which are responsible for glycogen synthesis.
The European Monitoring Centre for Drugs and Drug Addiction reports that the retail price of brown heroin varies from €14.5 per gram in Turkey to €110 per gram in Sweden, with most European countries reporting typical prices of €35–40 per gram. The price of white heroin is reported only by a few European countries and ranged between €27 and €110 per gram. The United Nations Office on Drugs and Crime claims in its 2008 World Drug Report that typical US retail prices are US$172 per gram.
== Applications == Quantitative/qualitative analysis of collective cell migration under changeable experimental conditions. Analysis of cell-matrix and cell-cell interactions with respect to cell migration. High-throughput screens for: Cancer cell migration genes Small molecules Drug discovery
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.